Belviq partners up with phentermine

Share this article:

Eisai's experiment with Belviq add-on weight-loss therapy is underway. MedPage Today reports that the two-part medication includes relative weight-loss newcomer Belviq with the older appetite suppressant phentermine, which was part of the disastrous combination weight-loss drug Fen-phen.

Despite the negative connotation, MedPage says the trial mix has been dubbed Belphen. The 12-week trial started in October and was sponsored by drug partners Arena and Eisai.

MedPage says the 225-patient study is a safety trial, and that the impact on weight loss and waist circumference are secondary endpoints. The study does not include a placebo group, nor does it include a echocardiogram, because Belviq's cardiovascular safety profile was sufficient for FDA approval.

The majority of experts told MedPage that they were OK with this study's lack of a cardiovascular component—phentermine was not considered the reason for Fen-Phen's heart damage. However, not everyone is sure this is the smartest way to go.

“This... looks a lot like an opportunity to repeat the dangerous follies of history,” Yale University's Prevention Research Center's David Katz told MedPage.

Share this article:

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.